Wolchko J Scott
Known title: President and CEOCIK: 0001586893
Associated companies
Transaction History
| FATE | ▼ Sell | Open Market | 14,391 | $63K | 1/9/2024 | View on chart |
| FATE | ▼ Sell | Open Market | 45,907 | $241K | 1/10/2023 | View on chart |
| FATE | ▲ Buy | Option Exercise | 6,246 | $17K | 7/22/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 2,703 | $88K | 7/22/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 620 | $21K | 7/22/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 2,923 | $92K | 7/22/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 30,000 | $81K | 7/21/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 19,171 | $634K | 7/21/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 10,829 | $352K | 7/21/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 10,000 | $27K | 4/22/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 838 | $29K | 4/22/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 9,162 | $316K | 4/22/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 30,000 | $81K | 4/21/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 22,715 | $785K | 4/21/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 4,062 | $145K | 4/21/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 2,220 | $81K | 4/21/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 1,003 | $38K | 4/21/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 10,000 | $27K | 1/21/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 10,000 | $380K | 1/21/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 30,000 | $82K | 1/20/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 30,000 | $1.2M | 1/20/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 10,047 | $487K | 1/11/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 4,519 | $222K | 1/11/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 20,894 | $986K | 1/10/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 101 | $5K | 1/10/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 13,161 | $610K | 1/10/2022 | View on chart |
| FATE | ▲ Buy | Grant | 86,475 | $0 | 11/19/2021 | View on chart |
| FATE | ▲ Buy | Option Exercise | 20,000 | $54K | 11/18/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 20,000 | $1.1M | 11/18/2021 | View on chart |
| FATE | ▲ Buy | Option Exercise | 10,000 | $27K | 10/22/2021 | View on chart |
| FATE | ▲ Buy | Option Exercise | 4,846 | $23K | 10/22/2021 | View on chart |
| FATE | ▲ Buy | Option Exercise | 15,154 | $41K | 10/22/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 30,000 | $1.8M | 10/22/2021 | View on chart |
| FATE | ▲ Buy | Option Exercise | 30,000 | $82K | 10/21/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 14,765 | $895K | 10/21/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 15,235 | $911K | 10/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial
Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.